Skip to content

Amanda Teeple

5 papers in the library · 9 citations · publishing 2025

Papers

Sort Most recent Most cited

Cost-per-remitter for esketamine nasal spray versus quetiapine for treatment-resistant depression.

Journal of comparative effectiveness research June 9, 2025 Kristin Clemens, Amanda Teeple, Benoit Rive et al.

Aim: Estimate the cost-per-remitter with esketamine nasal spray plus an oral antidepressant (ESK NS + OAD) versus quetiapine extended release plus an oral antidepressant (QTP XR + OAD) among adults with treatment-resistant depression (TRD). Materials & methods: An Excel-based model was developed to estimate the cost-per-remitter for ESK NS + OAD and QTP XR + OAD from the perspective of a US...

Health Care Resource Use and Medical Costs Among Patients With Major Depressive Disorder and Acute Suicidal Ideation or Behavior Initiated on Esketamine Nasal Spray or Traditional Treatments in the United States.

Clinical Therapeutics March 1, 2025 Lisa Harding, Maryia Zhdanava, Amanda Teeple et al. 3 citations

Major depressive disorder with acute suicidal ideation or behavior (MDSI) is a substantial humanistic, economic, and clinical burden on patients. Data on health care resource use (HRU) and costs among patients with MDSI initiated on esketamine nasal spray relative to traditional treatments are limited. This study sought to describe HRU and medical costs of patients with MDSI initiated on...

Characteristics of patients with major depressive disorder eligible for and prescribed esketamine, treatment outcomes and physician experiences: a physician and patient survey in the United States.

Current Medical Research and Opinion February 1, 2025 Manish K. Jha, Amanda Teeple, Jason Shepherd et al.

Esketamine is an FDA-approved treatment for treatment-resistant depression (TRD) or major depression with acute suicidal ideation or behavior (MDSI). This analysis addressed the lack of data on real-world characteristics of patients with TRD and MDSI or prescribed esketamine. Data were derived from the Adelphi Real World Depression Disease Specific Programme a cross-sectional survey of...

Esketamine Nasal Spray vs Quetiapine Extended-Release: Examining Work Productivity Loss and Related Costs in Patients With Treatment-Resistant Depression.

The Journal of Clinical Psychiatry January 27, 2025 Kristin Clemens, Amanda Teeple, Maryia Zhdanava et al. 2 citations

Objective: This post hoc analysis of the ESCAPE-TRD trial compared work productivity loss (WPL) and related costs among patients with treatment-resistant depression (TRD) receiving esketamine nasal spray or quetiapine extended release in combination with an oral antidepressant. Methods: Adults with TRD randomized to receive esketamine (56/84 mg) or quetiapine (150-300 mg) combined with ongoing...

Impact of social determinants of health on esketamine nasal spray initiation among patients with treatment-resistant depression in the United States.

Journal of managed care & specialty pharmacy 2025 Kristin Clemens, Maryia Zhdanava, Amanda Teeple et al. 4 citations

Disparities in mental health care access and health outcomes based on sociodemographic factors in the United States have been extensively documented. However, there is limited knowledge regarding these socioeconomic factors with respect to initiation of esketamine nasal spray, a novel therapy for treatment-resistant depression (TRD). To evaluate the association of socioeconomic factors with the...